## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims**:

1. (currently amended) Method for treatment of osteoporosis, comprising:

exposing a patient to [[of]] electromagnetic signals generated by pulsating, impulse-modulated direct current, ~~where the frequency is~~ having a frequency of 1 to 30 Hz and ~~the~~ a field strength of 1 to 20 G; and

administering Botulinum toxin as an adjuvant to the exposure of the patient to the electromagnetic signals.

2. (previously presented) Method according to claim 1, characterised in that the modulation form is quasi-rectangular.

3. (previously presented) Method according to claim 1 , characterised in that the frequency is approximately 5 to 15 Hz.

4. (previously presented) Method according to claim 1, characterised in that the field strength is approximately 10 to 15 G.

5. (previously presented) Method according to claim 4, characterised in that the preferred field strength is approximately 12.5 G.

6. (previously presented) Method according to claim 1, characterised in that the pulses are modulated.

7. (currently amended) Method for ~~the~~ administering a treatment to a patient including administration of a neurotoxin, the method comprising:

~~preparation of~~ providing a pharmaceutical composition comprising Botulinum toxin ~~for the treatment of osteoporosis in patients who are~~;

administering the Botulinum toxin intramuscularly, intravenously, or subcutaneously;

~~simultaneously exposed~~ in combination with said administering the Botulinum toxin, exposing the patient to electromagnetic signals generated by pulsating, pulse-modulated, unidirectional, direct current, with frequency between 1 and 30 Hz and field strength, 1 to 20 G.

8. (previously presented) Method according to claim 7, characterised in that the modulation form is quasi-rectangular.

9. (previously presented) Method according to claim 7 , characterised in that the frequency is approximately 5 to 15 Hz.

10. (previously presented) Method according to claim 7, characterised in that the field strength is approximately 10 to 15 G.

11. (previously presented) Method according to claim 10, characterised in that the field strength is approximately 12.5 G

12. (previously presented) Method according to claim 7, characterised in that the pulses are modulated.

13. (currently amended) Method according to claim 7, characterised ~~in that the~~ by using a dose of Botulinum toxin Type A ~~used is~~ in the range of 20U to 600U, applied as a neurotoxin adjuvant to said exposing the patient to electromagnetic signals.

14. (currently amended) Method according to claim ~~13~~ 7, characterised ~~in that~~ by using Botulinum toxin Type A ~~used is~~ in the range of 50U to 300U, applied as a neurotoxin adjuvant to said exposing the patient to electromagnetic signals.

15. (currently amended) Method according to claim 7, characterised ~~in that~~ by using Botulinum toxin Type B ~~used is~~ in the range 1U to 2000U, applied as a neurotoxin adjuvant to said exposing the patient to electromagnetic signals.

16. (new) Method according to claim 1, characterised by using a dose of Botulinum toxin Type A in the range of 20U to 600U, applied as a neurotoxin adjuvant to said exposing the patient to electromagnetic signals.

17. (new) Method according to claim 1, characterised by using a dose of Botulinum toxin Type A in the range of 50U to 300U, applied as a neurotoxin adjuvant to said exposing the patient to electromagnetic signals.

18. (new) Method according to claim 1, characterised by using a dose of Botulinum toxin Type B in the range 1U to 2000U, applied as a neurotoxin adjuvant to said exposing the patient to electromagnetic signals.